Home › Funds › Stonepine Capital Management, LLC › XLO

Stonepine Capital Management, LLC position in XLO

XILIO THERAPEUTICS INC · Health Care

Stonepine Capital Management, LLC reported holding 189,092 shares of XLO (XILIO THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.7M, representing 1.31% of its reported portfolio and ranking #18 among its reported holdings. Stonepine Capital Management, LLC has disclosed XLO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

Latest position (Q3 2026)189.09K sh
Reported value held$1.71M
Portfolio Weight1.31%
First reportedQ4 2025
Last changeReduce
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Stonepine Capital Management, LLC's XLO position evolved

Stonepine Capital Management, LLC first disclosed a stake in XLO in Q4 2025 at 126,270 shares (US$81K). The position peaked in Q2 2026 at 225,994 shares, worth US$2.2M. Across 4 filings, Stonepine Capital Management, LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 189,092 shares valued at US$1.7M — a reduction of -36,902 shares quarter over quarter.. Notable position changes include a 49% trim in Q1 2026 (shares rose 14% over the following quarter), a 252% increase in Q2 2026 (shares fell 6% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 126.27K $80.84K New
Q1 2026 64.16K $539.60K Reduce
Q2 2026 225.99K $2.17M Add
Q3 2026 189.09K $1.71M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XLO and 13F data

XLO (XILIO THERAPEUTICS INC) is a Health Care company. 26 other funds we track also report a position in XLO — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$6.4M), GILEAD SCIENCES, INC. (US$5.9M), Frazier Life Sciences Management, L.P. (US$4.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XLO

All XLO fund holders →

FAQ

How long has Stonepine Capital Management, LLC held XLO?

Stonepine Capital Management, LLC has disclosed XLO holdings in 4 of the last 4 reported quarters, going back to Q4 2025.

What is Stonepine Capital Management, LLC's current position in XLO?

As of Q3 2026, Stonepine Capital Management, LLC holds 189.09K shares of XLO (XILIO THERAPEUTICS INC), valued at $1.71M, representing 1.31% of its reported portfolio and ranking #18.

Has Stonepine Capital Management, LLC been buying or selling XLO?

In the latest 13F filing (Q3 2026), Stonepine Capital Management, LLC reduced its position in XLO. The position peaked in Q2 2026 at 225.99K shares.

Which other funds hold XLO?

Other major institutional holders of XLO include Bain Capital Life Sciences Investors, LLC, GILEAD SCIENCES, INC., Frazier Life Sciences Management, L.P., among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.